Professor Robert Rintoul
UKLCC Clinical Lead
Robert Rintoul is Professor of Thoracic Oncology in the Department of Oncology, University of Cambridge and Honorary Consultant Respiratory Physician, Royal Papworth Hospital. He qualified in medicine from the University of Edinburgh having undertaken his pre-clinical training at the University of St Andrews. He subsequently trained in respiratory medicine in London and Edinburgh. Professor Rintoul received his doctorate from the University of Edinburgh for research investigating mechanisms underlying resistance to chemotherapy in small cell lung cancer.
He was appointed consultant in respiratory medicine specialising in thoracic oncology at Royal Papworth Hospital in 2005 before moving to the University of Cambridge in 2017. Professor Rintoul is co-lead of the Thoracic Cancer Programme of the Cancer Research UK Cambridge Cancer Centre and Director of the Papworth Trials Unit Collaboration. Since 2021 he has been the Clinical Lead of the Clinical Advisory Group of the UK Lung Cancer Coalition.
His research is focused on clinical trials, translational research and tissue banking in malignant mesothelioma and early-stage lung cancer. He has a particular interest in biomarker research for detection of early-stage disease/CT screening. In 2014 he founded Mesobank UK, the UK national bioresource for malignant mesothelioma (www.mesobank.com). His research is funded by NIHR Cambridge Biomedical Research Centre, Cancer Research UK, Medical Research Council and Asthma and Lung UK.
He was appointed consultant in respiratory medicine specialising in thoracic oncology at Royal Papworth Hospital in 2005 before moving to the University of Cambridge in 2017. Professor Rintoul is co-lead of the Thoracic Cancer Programme of the Cancer Research UK Cambridge Cancer Centre and Director of the Papworth Trials Unit Collaboration. Since 2021 he has been the Clinical Lead of the Clinical Advisory Group of the UK Lung Cancer Coalition.
His research is focused on clinical trials, translational research and tissue banking in malignant mesothelioma and early-stage lung cancer. He has a particular interest in biomarker research for detection of early-stage disease/CT screening. In 2014 he founded Mesobank UK, the UK national bioresource for malignant mesothelioma (www.mesobank.com). His research is funded by NIHR Cambridge Biomedical Research Centre, Cancer Research UK, Medical Research Council and Asthma and Lung UK.